Clean Science and Technology Limited share price
NSE: CLEAN · ISIN INE227W01023
Key numbers
- Market cap
- ₹ 8,580 Cr
- Current price
- ₹ 807.25
- 52-week high / low
- ₹ 1,118 / 652
- Stock P/E
- 37.2
- Book value
- ₹ 148.9
- Dividend yield
- 0.74%
- ROCE
- 20.6%
- ROE
- 15.3%
- Debt to equity
- 0.00
- Sales growth (3 yrs)
- 0.6%
- Profit growth (3 yrs)
- -8.0%
- 1-year return
- -28.4%
About Clean Science and Technology Limited
Clean Science and Technology Limited, together with its subsidiaries, manufactures fine and specialty chemicals in India, China, the United States, Europe, and internationally. It operates through Performance Chemicals, FMCG Chemicals, and Pharma & Agro Intermediates segments. The company offers performance chemicals, including monomethyl ether of hydroquinone, butylated hydroxy anisole, ascorbyl palmitate, tertiary butyl hydroquinone, hydroquinone, hindered amine light stabilisers, catechol, and butylated hydroxytoluene, as well as clean antiOX 962, 4-oxo tempo, 4-butoxy tempo, clean light stab 770, 4-hydroxy tempo, and dimethyl sebacate. It also provides FMCG chemicals, such as 4-methoxy acetophenone, anisole, guaiacol, butylated hydroxy anisole, l-ascorbyl palmitate, para di-methoxy benzene, and ortho methoxy toluene. In addition, the company offers pharmaceutical and agro intermediates, which includes dicyclohexyl carbodiimide, veratrole, DHDT, para benzoquinone, para di-methoxy benzene, anisole, and ortho methoxy toluene. It serves acrylic monomers and polymers; animal nutrition and feed; coatings, resins, paints, and inks; cosmetic and personal care; electronics and…
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 264 | 243 | 220 | 249 | 268 |
| Operating profit | 105 | 100 | 72 | 96 | 96 |
| Net profit | 74 | 70 | 46 | 58 | 73 |
| EPS (₹) | 6.97 | 6.59 | 4.32 | 5.48 | 6.90 |
Concall summary (2026-08-06)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- The Q4 FY26 EBITDA and PAT after adjusting the one -off operating expense transactions is roughly INR 83 crores and INR 53 crores, respectively.
- HALS is now 22% of our sales, and we have been able to Clean Science and Technology Limited August 01, 2026 derisk our reliance on the top 4 legacy products by moderating their share from 85% in Q4 FY23 to 60% this quarter.
Growth & demand
- Thereby, the current quarter EBITDA and PAT reflected a growth of 5% and 37%, respectively.
- On a sequential basis, the consolidate d revenues grew by 7% to INR 264 crores.
Margins & costs
- On a sequential basis, the revenue improved by 5% to INR 203 crores, largely due to increase in realization in all the products.
- The EBITDA and the PAT margins are at 43% and 36%, translating into an EBITDA of INR87 crores and PAT of INR 73 crores.
Capex & expansion
- The stabilization of the hydroquinone and catechol plant has been largely completed and our operations are now progressing well.
- On a capex update, the Performance Chemical 2 will get commer cialized by quarter 3 FY27.
Balance sheet & cash
- On consolidated business performance, the HALS scaleup continues to drive operating leverage and sustainable profit improvement.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.